Sonoma Pharmaceuticals, Inc. (SNOA)
USD 2.45
(6.99%)
USD 2.45
(6.99%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 12.73 Million USD | -4.05% |
| 2023 | 13.27 Million USD | 5.1% |
| 2022 | 12.62 Million USD | -32.21% |
| 2021 | 18.62 Million USD | -1.62% |
| 2020 | 18.93 Million USD | -0.18% |
| 2019 | 18.97 Million USD | 13.88% |
| 2018 | 16.65 Million USD | 29.89% |
| 2017 | 12.82 Million USD | -14.98% |
| 2016 | 15.08 Million USD | 8.88% |
| 2015 | 13.85 Million USD | 1.36% |
| 2014 | 13.66 Million USD | -11.55% |
| 2013 | 15.45 Million USD | 21.25% |
| 2012 | 12.74 Million USD | 30.65% |
| 2011 | 9.75 Million USD | 32.46% |
| 2010 | 7.36 Million USD | 36.67% |
| 2009 | 5.38 Million USD | 40.5% |
| 2008 | 3.83 Million USD | -15.58% |
| 2007 | 4.54 Million USD | 75.81% |
| 2006 | 2.58 Million USD | 90.56% |
| 2005 | 1.35 Million USD | 50.33% |
| 2004 | 902 Thousand USD | -63.48% |
| 2003 | 2.47 Million USD | 23.5% |
| 2002 | 2 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 3.13 Million USD | 14.9% |
| 2024 Q1 | 3.42 Million USD | 13.7% |
| 2024 Q2 | 2.73 Million USD | -20.31% |
| 2024 FY | 12.73 Million USD | -4.05% |
| 2024 Q4 | 3.43 Million USD | 9.59% |
| 2023 Q2 | 3.33 Million USD | -16.37% |
| 2023 Q1 | 3.98 Million USD | 73.32% |
| 2023 Q4 | 3.01 Million USD | 2.38% |
| 2023 FY | 13.27 Million USD | 5.1% |
| 2023 Q3 | 2.94 Million USD | -11.62% |
| 2022 Q2 | 3.74 Million USD | 1.63% |
| 2022 Q4 | 2.29 Million USD | -20.81% |
| 2022 FY | 12.62 Million USD | -32.21% |
| 2022 Q1 | 3.68 Million USD | 70.79% |
| 2022 Q3 | 2.9 Million USD | -22.49% |
| 2021 Q2 | 5.76 Million USD | -20.47% |
| 2021 FY | 18.62 Million USD | -1.62% |
| 2021 Q1 | 7.25 Million USD | 58.42% |
| 2021 Q4 | 2.15 Million USD | -56.3% |
| 2021 Q3 | 4.93 Million USD | -14.44% |
| 2020 Q2 | 4.96 Million USD | 5.46% |
| 2020 FY | 18.93 Million USD | -0.18% |
| 2020 Q3 | 4.67 Million USD | -5.84% |
| 2020 Q4 | 4.57 Million USD | -2.12% |
| 2020 Q1 | 4.71 Million USD | 7.51% |
| 2019 Q2 | 4.93 Million USD | 13.05% |
| 2019 Q3 | 5.28 Million USD | 6.9% |
| 2019 Q1 | 4.36 Million USD | 19.53% |
| 2019 Q4 | 4.38 Million USD | -17.01% |
| 2019 FY | 18.97 Million USD | 13.88% |
| 2018 Q3 | 4.84 Million USD | 11.98% |
| 2018 FY | 16.65 Million USD | 29.89% |
| 2018 Q4 | 3.65 Million USD | -24.53% |
| 2018 Q2 | 4.32 Million USD | 12.78% |
| 2018 Q1 | 3.83 Million USD | -4.82% |
| 2017 Q3 | 3.36 Million USD | -18.18% |
| 2017 Q4 | 4.02 Million USD | 19.88% |
| 2017 Q1 | 3.81 Million USD | 7.96% |
| 2017 FY | 12.82 Million USD | -14.98% |
| 2017 Q2 | 4.1 Million USD | 7.79% |
| 2016 Q3 | 3.82 Million USD | -5.77% |
| 2016 FY | 15.08 Million USD | 8.88% |
| 2016 Q2 | 4.05 Million USD | 10.16% |
| 2016 Q1 | 3.68 Million USD | -7.54% |
| 2016 Q4 | 3.53 Million USD | -7.59% |
| 2015 Q4 | 3.98 Million USD | 23.68% |
| 2015 Q3 | 3.21 Million USD | -1.41% |
| 2015 Q2 | 3.26 Million USD | -3.77% |
| 2015 Q1 | 3.39 Million USD | 16.4% |
| 2015 FY | 13.85 Million USD | 1.36% |
| 2014 Q3 | 3.29 Million USD | -19.47% |
| 2014 Q4 | 2.91 Million USD | -11.51% |
| 2014 FY | 13.66 Million USD | -11.55% |
| 2014 Q2 | 4.08 Million USD | 21.26% |
| 2014 Q1 | 3.37 Million USD | 1.11% |
| 2013 Q2 | 4.52 Million USD | 11.73% |
| 2013 FY | 15.45 Million USD | 21.25% |
| 2013 Q3 | 3.54 Million USD | -21.79% |
| 2013 Q1 | 4.05 Million USD | 20.89% |
| 2013 Q4 | 3.33 Million USD | -5.79% |
| 2012 Q1 | 2.94 Million USD | 8.45% |
| 2012 Q3 | 2.79 Million USD | -23.83% |
| 2012 FY | 12.74 Million USD | 30.65% |
| 2012 Q4 | 3.35 Million USD | 20.11% |
| 2012 Q2 | 3.66 Million USD | 24.59% |
| 2011 Q2 | 2.46 Million USD | 8.92% |
| 2011 Q3 | 2.31 Million USD | -6.2% |
| 2011 Q4 | 2.71 Million USD | 17.21% |
| 2011 FY | 9.75 Million USD | 32.46% |
| 2011 Q1 | 2.26 Million USD | 1.43% |
| 2010 Q3 | 1.61 Million USD | -3.53% |
| 2010 Q2 | 1.67 Million USD | -9.47% |
| 2010 FY | 7.36 Million USD | 36.67% |
| 2010 Q1 | 1.84 Million USD | 25.22% |
| 2010 Q4 | 2.23 Million USD | 38.38% |
| 2009 Q4 | 1.47 Million USD | 20.8% |
| 2009 Q3 | 1.22 Million USD | -17.56% |
| 2009 Q2 | 1.48 Million USD | 22.3% |
| 2009 Q1 | 1.21 Million USD | 30.78% |
| 2009 FY | 5.38 Million USD | 40.5% |
| 2008 FY | 3.83 Million USD | -15.58% |
| 2008 Q2 | 977 Thousand USD | 12.82% |
| 2008 Q1 | 866 Thousand USD | -25.47% |
| 2008 Q3 | 1.06 Million USD | 9.11% |
| 2008 Q4 | 926 Thousand USD | -13.13% |
| 2007 Q3 | 1.05 Million USD | -9.7% |
| 2007 Q1 | 1.16 Million USD | 55.13% |
| 2007 Q4 | 1.16 Million USD | 10.46% |
| 2007 FY | 4.54 Million USD | 75.81% |
| 2007 Q2 | 1.16 Million USD | 0.0% |
| 2006 Q2 | 541 Thousand USD | 0.0% |
| 2006 Q3 | 751 Thousand USD | 38.82% |
| 2006 Q4 | 751 Thousand USD | 0.0% |
| 2006 FY | 2.58 Million USD | 90.56% |
| 2006 Q1 | 541 Thousand USD | 59.59% |
| 2005 Q2 | 339 Thousand USD | 0.0% |
| 2005 Q3 | 339 Thousand USD | 0.0% |
| 2005 FY | 1.35 Million USD | 50.33% |
| 2005 Q1 | 339 Thousand USD | 0.0% |
| 2005 Q4 | 339 Thousand USD | 0.0% |
| 2004 FY | 902 Thousand USD | -63.48% |
| 2003 FY | 2.47 Million USD | 23.5% |
| 2002 FY | 2 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 97.753% |
| Embecta Corp. | 1.12 Billion USD | 98.864% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 97.384% |
| Dynavax Technologies Corporation | 232.28 Million USD | 94.517% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 89.053% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 98.113% |
| PainReform Ltd. | - USD | -Infinity% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 74.824% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 47.142% |
| SCYNEXIS, Inc. | 140.14 Million USD | 90.913% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -560.359% |
| Cosmos Health Inc. | 53.37 Million USD | 76.141% |
| Journey Medical Corporation | 79.18 Million USD | 83.917% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 47.142% |
| Safety Shot Inc | 202.67 Thousand USD | -6183.614% |
| Alpha Teknova, Inc. | 36.68 Million USD | 65.285% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 97.258% |
| Bright Green Corporation | 401.49 Thousand USD | -3071.927% |
| Procaps Group, S.A. | 409.92 Million USD | 96.893% |
| Theratechnologies Inc. | 81.76 Million USD | 84.425% |
| Harrow Health, Inc. | 130.19 Million USD | 90.218% |
| Biofrontera Inc. | 34.07 Million USD | 62.622% |
| DURECT Corporation | 8.54 Million USD | -48.982% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 97.904% |
| Cronos Group Inc. | 88.84 Million USD | 85.665% |
| OptiNose, Inc. | 70.98 Million USD | 82.06% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 97.124% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -95.527% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 97.06% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -3.971% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 67.802% |
| Radius Health, Inc. | 2.88 Billion USD | 99.558% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 60.583% |
| ProPhase Labs, Inc. | 44.38 Million USD | 71.307% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 98.749% |
| Procaps Group S.A. | 409.92 Million USD | 96.893% |
| Alvotech | 91.43 Million USD | 86.072% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -878.111% |
| Viatris Inc. | 15.42 Billion USD | 99.917% |
| Rockwell Medical, Inc. | 83.61 Million USD | 84.769% |
| Aytu BioPharma, Inc. | 81 Million USD | 84.278% |
| SIGA Technologies, Inc. | 139.91 Million USD | 90.898% |
| Tilray Brands, Inc. | 788.94 Million USD | 98.386% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 90.071% |
| Shineco, Inc. | 9.8 Million USD | -29.924% |
| PetIQ, Inc. | 1.1 Billion USD | 98.844% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -106025.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.325% |
| Alimera Sciences, Inc. | 80.75 Million USD | 84.23% |
| Silver Spike Investment Corp. | 11.72 Million USD | -8.641% |
| Assertio Holdings, Inc. | 152.06 Million USD | 91.626% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -118.725% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | 26.882% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -1083.105% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 54.458% |
| Hempacco Co., Inc. | 4.04 Million USD | -214.784% |
| Talphera, Inc. | 651 Thousand USD | -1856.221% |
| Alvotech | 91.43 Million USD | 86.072% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 95.978% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.018% |
| Currenc Group, Inc. | 53.25 Million USD | 76.087% |
| Kamada Ltd. | 144.75 Million USD | 91.203% |
| Indivior PLC | 1.09 Billion USD | 98.835% |
| Evoke Pharma, Inc. | 5.18 Million USD | -145.82% |
| Flora Growth Corp. | 76.07 Million USD | 83.259% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -1083.105% |
| Evolus, Inc. | 202.08 Million USD | 93.698% |
| HUTCHMED (China) Limited | 837.99 Million USD | 98.48% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 98.024% |
| Akanda Corp. | 2.16 Million USD | -489.569% |